Project MK-3475 Prot. 630

Basic data

Title:
MK-3475 Prot. 630
Duration:
01/07/2019 to 30/09/2021
Abstract / short description:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma
(LA cSCC) (KEYNOTE-630)

Involved staff

Managers

Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Haar, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.